Emyria Ltd (ASX:EMD)‘s Dr Michael Winlo speaks to Proactive after the company received ethics approval for its phase one clinical trial of EMD-RX5, a proprietary, highly bioavailable oral formulation of ultra-pure CBD. The phase one trial is an important first step towards registration and will evaluate the bioavailability of EMD-RX5 as compared to Epidyolex — the only CBD medicine formally registered with the Therapeutic Goods Administration and the Food and Drug Administration.
